Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)
Sponsor: Allergan
Listed as NCT02462486, this PHASE3 trial focuses on Macular Degeneration and remains completed. Sponsored by Allergan, it has been updated 19 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 14 earlier versions
-
Aug 2019 — Aug 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .